Trial
NCT04460105
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Shire
Collaborators
Takeda Development Center Americas, Inc.
Condition
COVID-19 Pneumonia
Intervention
Lanadelumab
Why stopped
Study was withdrawn due to challenges in site recruitment and lack of patient enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-12